▲ Peaking
Business
Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has unveiled clinical trial data for a KRAS-targeting drug combination aimed at treating metastatic pancreatic cancer.
2 trends tracked about this subject — the full history, oldest to newest below.
Revolution Medicines has unveiled clinical trial data for a KRAS-targeting drug combination aimed at treating metastatic pancreatic cancer.
Experimental drug daraxonrasib is drawing attention for its performance in clinical trials targeting advanced pancreatic cancer.